Neupro (Rotigotine)

Rotigotine, the active ingredient in Neupro, is a dopamine agonist presented as a 2‑8 mg/24 h transdermal patch for transdermal use. It treats Parkinson's disease and restless legs syndrome in adults.

GNH USA supplies Neupro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neupro is a dopamine agonist indicated for movement‑disorder conditions.

- Parkinson's disease: improves motor symptoms and reduces OFF periods in patients with idiopathic Parkinson's disease. - Restless legs syndrome: lessens the urge to move the legs and improves sleep quality in adults with moderate to severe RLS.

Common Side Effects: - Application site reactions: erythema, pruritus, or edema at the patch site. - Nausea or vomiting. - Dizziness or light‑headedness. - Somnolence or fatigue. - Dry mouth. - Increased sweating.

Serious or Rare Side Effects: - Hallucinations or psychotic symptoms. - Impulse control disorders such as compulsive gambling or hypersexuality. - Severe hypotension or syncope. - Allergic reactions including skin necrosis or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors. - Cardiovascular assessment: monitor for orthostatic hypotension, especially in elderly patients. - Psychiatric history: watch for hallucinations, confusion, or impulse control disorders. - Hepatic function: consider dose adjustment in moderate hepatic impairment. - Concomitant dopamine antagonists: avoid or use with caution due to antagonistic effects. - Hypersensitivity: discontinue if allergic reaction to rotigotine or patch excipients occurs. - Store at room temperature: keep in the original pouch, protect from moisture and direct sunlight.

Rotigotine may interact with several drug classes.

Major Interactions (Avoid): - MAO‑B inhibitors (e.g., selegiline, rasagiline): risk of hypertensive crisis. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase rotigotine exposure. - Potent CYP2C19 inhibitors (e.g., omeprazole): can raise plasma levels. - Antipsychotics with dopamine antagonism (e.g., haloperidol): reduce therapeutic effect. - Other dopamine agonists: additive dopaminergic effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: enhanced hypotensive effect. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may lower rotigotine concentrations. - Alcohol: may increase central nervous system depression. - SSRIs or SNRIs: potential for increased nausea. - Nicotine replacement therapy: may affect patch adhesion and absorption.